Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC. Aim of this research was to study the prognostic and predictive value of tumor (MET, the rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Salvagni, Stefania, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Trojan, Jörg, De Toni, Enrico N., Weiss, Alan, Miles, Steven, Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E., Wang, Yunxia, Shuster, Dale, Schwartz, Brian E., Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341932/
https://www.ncbi.nlm.nih.gov/pubmed/27579536
http://dx.doi.org/10.18632/oncotarget.11621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341932/
https://www.ncbi.nlm.nih.gov/pubmed/27579536
http://dx.doi.org/10.18632/oncotarget.11621

Ejemplares similares